Prenatal Detection of Down Syndrome using Massively Parallel Sequencing (MPS): a rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, 24 October 2011

@article{Benn2012PrenatalDO,
  title={Prenatal Detection of Down Syndrome using Massively Parallel Sequencing (MPS): a rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, 24 October 2011},
  author={Peter Benn and Antoni Borrell and Howard Cuckle and Lorraine Dugoff and Susan J Gross and Joann Johnson and Ron Maymon and Anthony O Odibo and Peter Schielen and Kevin Spencer and David Wright and Yuval Yaron},
  journal={Prenatal Diagnosis},
  year={2012},
  volume={32}
}
Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT, USA Prenatal Diagnosis Unit, Institute of Gynecology, Obstetrics and Neonatology, Hospital Clinic, Maternitat Campus, University of Barcelona Medical School, Catalonia, Spain Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY, USA Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA Department of Obstetrics and… 

Topics from this paper

Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis
TLDR
This Statement replaces the January 2011 Statement (Prenatal Diagnosis 2011;31:519–522) and the Rapid Response Statement (RIVM 2012;32:1–2).
Current controversies in prenatal diagnosis 1: should noninvasive DNA testing be the standard screening test for Down syndrome in all pregnant women?
TLDR
This work presents a novel and scalable approach called "Smart Prenatal Diagnosis and Therapy,” which aims to provide real-time information about the prognosis and treatment preferences of mothers and babies during the first trimester of pregnancy.
The Evolution of Prenatal Diagnosis from Invasive Procedures to Non-invasive Prenatal Testing (NIPT)
TLDR
Prenatal Genetic Diagnosis Unit, Genetic Institute, Tel Aviv Sourasky Medical Center, 6 Weizmann Street,Tel Aviv, 64239, Israel, and Rachel Michaelson-Cohen,Department of Obstetrics & Gynecology, Shaare Zedek Medical center, Hebrew University of Jerusalem, Israel.
Current status in non-invasive prenatal detection of Down syndrome, trisomy 18, and trisomy 13 using cell-free DNA in maternal plasma.
  • S. Langlois, Jo-Ann K. Brock
  • Medicine
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
  • 2013
TLDR
Although testing of cell-free fetal DNA in maternal plasma appears very promising as a screening test for Down syndrome and other trisomies, studies in average-risk pregnancies and a significant reduction in the cost of the technology are needed before this can replace the current maternal screening approach using biochemical serum markers.
Prenatal peptide treatment appears promising in Down syndrome mouse model
  • D. Levenson
  • Medicine, Biology
    American journal of medical genetics. Part A
  • 2013
TLDR
The fetal fraction of cell-free DNA in maternal plasma is not affected by a priori risk of fetal trisomy, and the NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy is adopted.
Detection of chromosome abnormalities using current noninvasive prenatal testing: A multi-center comparative study.
TLDR
NIPT is a quick and reliable screening method for detecting fetal chromosome aneuploidies and subchromosome deletions/duplications and challenges remain for the comprehensive clinical application of NIPT.
Clinical implementation of cell‐free DNA‐based aneuploidy screening: perspectives from a national audit
  • L. Hui, M. Teoh, +5 authors S. Walker
  • Medicine
    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • 2015
TLDR
A group of Australian obstetric sonologists formed a collaboration to document the collective national experience of non-invasive prenatal testing, across a range of practice types and using a variety of NIPT providers.
Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies.
TLDR
A small number of cases of occult malignancy were subsequently diagnosed among pregnant women whose noninvasive prenatal testing results showed discordance with the fetal karyotype, and the clinical importance of these findings will require further research.
Non-Invasive Prenatal Chromosomal Aneuploidy Testing - Clinical Experience: 100,000 Clinical Samples
TLDR
The accuracy and NIPT assay positivity rate are as predicted by clinical validations and the test demonstrates improvement in the current standard of care.
Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol
TLDR
The results of this study will make a significant contribution to policy decisions around the implementation of NIPT for aneuploidies within the UK NHS and the laboratory standards for testing and reporting, education materials and counselling strategies developed as part of the study are likely to underpin the introduction of NipT into NHS practice.
...
1
2
3
4
5
...

References

SHOWING 1-7 OF 7 REFERENCES
Aneuploidy screening: a position statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, January 2011
TLDR
Prenatal screening has emphasized the detection of Down syndrome, but it is recognized that many of the screening tests have a variable potential to detect other aneuploidies, some other genetic disorders, specific fetal anatomic abnormalities and pregnancy complications such as preeclampsia.
Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study
TLDR
Multiplexed maternal plasma DNA sequencing analysis could be used to rule out fetal trisomy 21 among high risk pregnancies and if referrals for amniocentesis or chorionic villus sampling were based on the sequencing test results, about 98% of the invasive diagnostic procedures could be avoided.
DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study
TLDR
Measurement of circulating cell-free DNA in maternal plasma DNA detects nearly all cases of Down syndrome at a very low false-positive rate, and can substantially reduce the need for invasive diagnostic procedures and attendant procedure-related fetal losses.
Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting.
TLDR
Extending the scope of previous reports, this study demonstrates that plasma DNA sequencing is a viable method for noninvasive detection of fetal trisomy 21 and warrants clinical validation in a larger multicenter study.
Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood.
TLDR
Massively parallel sequencing is capable of detecting multiple fetal chromosomal abnormalities from maternal plasma when an optimized algorithm is used.
Aneuploidy screening: a position statement on behalf of the Board of the International Society for Prenatal Diagnosis
  • Prenat Diagn
  • 2011
Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validation study
  • Brit Med J
  • 2011